Phase 1 Lung Cancer Trial, Recruiting NCT06128148 Sponsor: Guangzhou JOYO Pharma Co., Ltd Condition: Lung Cancer
Back to Lung Cancer

Phase 1 Lung Cancer Trial, Recruiting

NCT06128148
Recruiting Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 years or older.
  • People who have been diagnosed with locally advanced or metastatic solid tumour cancers (confirmed by laboratory testing of tissue or cell samples) that have a specific genetic change called a ROS1 fusion.
  • People whose cancer can be measured using standard imaging guidelines (called RECIST version 1.1).
  • People with a life expectancy of at least 3 months.
  • Other criteria specified in the trial protocol may also apply (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are currently taking part in another clinical trial that involves a treatment or therapy.
  • People who have a bowel or digestive condition (such as Crohn's disease, ulcerative colitis, or short gut syndrome) or any other condition that affects how the body absorbs medication.
  • People who have a history of severe allergic reactions, or who have had a severe allergic or sensitivity reaction to any ingredient in the study drug.
  • People who have a known active infection, whether bacterial or viral, including HIV.
  • Other criteria specified in the trial protocol may also apply (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Guangzhou JOYO Pharma Co., Ltd
Registry
ClinicalTrials.gov
Start date
4 May 2022
Est. completion
30 June 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The frequency and severity of adverse events of JYP0322

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov